Evidence map›Paper›PMID 33204857›Full record

ArticleClinical and translational radiation oncology2020

Treatment interruptions affect biochemical failure rates in prostate cancer patients treated with proton beam therapy: Report from the multi-institutional proton collaborative group registry.

James E Han, John Chang, Lane Rosen, William Hartsell, Henry Tsai, Jonathan Chen, Mark V Mishra, Daniel Krauss, J Isabelle Choi, Charles B Simone and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

James E HanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
John ChangDepartment of Radiation Oncology, Oklahoma Proton Center, Oklahoma City, OK, USA.
Lane RosenDepartment of Radiation Oncology, Willis Knighton Medical Center, Shreveport, LA, USA.
William HartsellDepartment of Radiation Oncology, Northwestern University, Chicago, IL, USA.
Henry TsaiProCure Proton Therapy Center, Somerset, NJ, USA.
Jonathan ChenDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Mark V MishraDepartment of Radiation Oncology, University of Maryland School of Medicine, MD, USA.
Daniel KraussDepartment of Radiation Oncology, Beaumont Hospital, Royal Oak, MI, USA.
J Isabelle ChoiDepartment of Radiation Oncology, New York Proton Center, New York, NY, USA.
Charles B SimoneDepartment of Radiation Oncology, New York Proton Center, New York, NY, USA.
Shaakir HasanDepartment of Radiation Oncology, New York Proton Center, New York, NY, USA.
New York Proton Center · USBeaumont Hospital, Royal Oak · USNorthwestern University · USProCure (United States) · USUniversity of California, Los Angeles · USUniversity of Maryland, Baltimore · USUniversity of Washington · USWillis-Knighton Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo date, no studies examining the effect of treatment interruptions (TI) with proton beam therapy (PBT) have been published. The goal of our study was to determine the predictors of TI amongst patients with prostate cancer (PCa) treated with PBT and to determine whether TI are associated with biochemical failure (BF). We hypothesized that any correlation between TI and biochemical control would be more pronounced in high risk groups.

methodsData for 4278 patients with PCa was obtained from the prospectively collected Proton Collaborative Group (PCG) data registry. Univariate and multivariate logistic regression analysis (MVA) was used to model possible predictors of BF. A subset analysis was performed for high risk patients treated with ADT and PBT. Finally, propensity score (PS) analysis was performed to account for any indication bias caused by lack of randomization.

resultsTotal treatment duration (OR, 1.05 [1.04-1.06]; p < 0.001) increased the likelihood of TI on MVA. TI did not have a statistically significant correlation with BF (OR, 1.44 [0.86-2.39]; p = 0.162) amongst PS matched patients. However, on subset analyses of high risk group patients with PS matching, there was a trend towards worse BF in patients with TI (OR 3.85; 95%CI (0.96-15.44); p = 0.057).

conclusionIn the first analysis of its kind, the results suggest that TI in high risk PCa patients treated with PBT and ADT have worse BF rates. Interventions such as increased patient education, proper maintenance of proton facilities, and decreasing total treatment duration with alternative fractionation schedules may help avoid the unintended negative effects on tumor control due to TI. However, future analyses on a larger patient population is needed.

Indexed as

Prostate cancerProton beam therapyTreatment interruptions

Identifiers

PMID33204857
PMCPMC7649394
OpenAlexW3093987407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.